Document Type
Poster
Publication Date
5-1-2019
Institution/Department
Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Cancer Risk and Prevention Program
MeSH Headings
Medical Oncology, Physician-Patient Relations
Abstract
Background:
• Genomic tumor testing (GTT) is a new technology and a cornerstone of the “precision medicine” movement in cancer care.
• GTT uses next-generation genome sequencing technology to identify somatic variants in tumor cells.
• By identifying somatic variants that predict responses to cancer therapies, GTT can help tailor therapy to individual patients, making them more effective.
• However, due to the fact that GTT also detects many variants of uncertain significance, its clinical value is currently unproven.
• When using GTT, physicians counsel patients about both its benefits and its limitations, but the ideal goals and content of these physician-patient discussions have not been clearly defined.
Recommended Citation
Mandeville, Hayley; Anderson, Eric; Murray, Kimberly; Gutheil, Caitlin; Waterston, Leo; Lucas, Lee; Duarte, Christine; Thomas, Christian; Miesfeldt, Susan; Helbig, Petra; Antov, Andrey; Rueter, Jens; and Han, Paul, "Physician-patient communication about genomic tumor testing: perceptions of oncology providers" (2019). Maine Medical Center. 701.
https://knowledgeconnection.mainehealth.org/mmc/701
Comments
Lambrew Research Retreat
Acknowledgements: The Maine Cancer Genomics Initiative (MCGI) is funded by the Harold Alfond Foundation, and conducted in partnership with the Jackson Laboratory and the MMCRI Center for Outcomes Research and Evaluation (CORE)